Đang chuẩn bị nút TẢI XUỐNG, xin hãy chờ
Tải xuống
Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học Wertheim cung cấp cho các bạn kiến thức về ngành y đề tài: Moving towards high density clinical signature studies with a human proteome catalogue developing multiplexing mass spectrometry assay panels. | Rezeli et al. Journal of Clinical Bioinformatics 2011 1 7 http www.jclinbioinformatics.eom content 1 1 7 JOURNAL OF CLINICAL BIOINFORMATICS SHORT REPORT Open Access Moving towards high density clinical signature studies with a human proteome catalogue developing multiplexing mass spectrometry assay panels 11 1.2 1 13 Melinda Rezeli Ákos Végvári Thomas E Fehniger Thomas Laurell Gyorgy Marko-Varga Abstract A perspective overview is given describing the current development of multiplex mass spectrometry assay technology platforms utilized for high throughput clinical sample analysis. The development of targeted therapies with novel personalized medicine drugs will require new tools for monitoring efficacy and outcome that will rely on both the quantification of disease progression related biomarkers as well as the measurement of disease specific pathway signaling proteins. The bioinformatics developments play a key central role in the area of clinical proteomics where targeted peptide expressions in health and disease are investigated in small- medium- and large-scaled clinical studies. An outline is presented describing applications of the selected reaction monitoring SRM mass spectrometry assay principle. This assay form enables the simultaneous description of multiple protein biomarkers and is an area under a fast and progressive development throughout the community. The Human Proteome Organization HUPO recently launched the Human Proteome Project HPP that will map the organization of proteins on specific chromosomes on a chromosome-by-chromosome basis utilizing the SRM technology platform. Specific examples of an SRM-multiplex quantitative assay platform dedicated to the cardiovascular disease area screening Apo A1 Apo A4 Apo B Apo CI Apo CII Apo CIII Apo D Apo E Apo H and CRP biomarkers used in daily diagnosis routines in clinical hospitals globally are presented. We also provide data on prostate cancer studies that have identified a variety of PSA isoforms .
